<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860938</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB 148/06</org_study_id>
    <nct_id>NCT00860938</nct_id>
  </id_info>
  <brief_title>Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD</brief_title>
  <official_title>Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study purpose is to evaluate if subjects with chronic obstructive pulmonary disease (COPD)
      are more likely to be responsive to additional inhaled corticosteroids if they have a
      positive response to hyperosmolar challenge with mannitol than if their response is negative.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with chronic obstructive pulmonary disease (COPD), the treatment with inhaled
      corticosteroids (ICS) is controversial. Preliminary results of our recent pilot study in 30
      COPD patients showed for the first time, that ICS response mey be predicted by a
      bronchoprovocation challenge test with mannitol. However, this finding needs to be proven in
      a placebo-controlled trial. For this cohort study, 100 corticosteroid-naive, non reversible
      (FEV1) patients with COPD will be recruited. Spirometry before and after bronchodilation will
      be measured at study entry and at four weeks run-in (only tiotropium) and at three month of
      treatment with tiotropium and ICS or placebo. Quality of life (St. George Respiratory Quality
      of Life Questionnaire) and exacerbation rate of COPD will be assessed. Measurement of exhaled
      nitric oxide and mannitol challenge will be performed at study entry and at 1 and 4 month.
      Primary endpoint will be improvement in FEV1 in each group (positive and negative mannitol
      challenge) after 3 months follow up. Secondary endpoints will be the difference in
      dose-response-curve in the mannitol challenge, exacerbation rate and change in quality of
      life after three month follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in lung function (FEV1,FVC, FEV1/VC</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion who complete follow-up without developing an exacerbation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exhaled NO</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PD15 FEV1 to mannitol and RDR mannitol</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo</description>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Miflonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1/FVC &lt; 70%

          -  FEV1 % predicted &gt; 60%

        Exclusion Criteria:

          -  Other major disease

          -  Asthma

          -  Currently taking inhaled corticosteroids

          -  oral corticosteroids in the last 3 month

          -  significant cardiovascular disease

          -  pregnancy/breast feeding

          -  current use of salmeterol or other long acting bronchodilator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg D Leuppi, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg D Leuppi, MD PhD</last_name>
      <phone>+41 61 328 69 21</phone>
      <email>leuppij@uhbs.ch</email>
    </contact>
    <investigator>
      <last_name>Jörg D Leuppi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 12, 2009</last_update_submitted>
  <last_update_submitted_qc>March 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>PD Dr. J. Leuppi</name_title>
    <organization>University Hospital Basel</organization>
  </responsible_party>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>COPD</keyword>
  <keyword>mannitol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 4, 2017</submitted>
    <returned>January 30, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

